by admin | 16th March 2023 | News
OKYO Pharma Limited (“OKYO” or the “Company”) Closing of Global Private Placement London, March 16, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat... by admin | 15th March 2023 | News
OKYO Pharma Limited (“OKYO” or the “Company”) Grant of options –PDMR dealing London, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is... by admin | 14th March 2023 | News
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY... by admin | 13th March 2023 | News
London and New York, NY, March 13, 2023 OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar... by admin | 28th February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease London and New York, NY, February 28, 2023 – OKYO Pharma Limited (LSE:...